• Antiviral therapy is not recommen

• Antiviral therapy is not recommended and can be deferred in persons without clinical evidence of cirrhosis (or based on APRI score ≤2 in adults), and with persistently normal ALT levels and low levels of HBV DNA replication (HBV DNA 20 000 IU/ mL but persistently normal ALT levels;
--HBeAg-negative persons without cirrhosis aged 30 years or less, with HBV DNA levels that fluctuate between 2000 and 20 000 IU/mL, or who have intermittently abnormal ALT levels;
››Where HBV DNA testing is not available: Persons without cirrhosis aged 30 years or less, with persistently normal ALT levels, regardless of HBeAg status

Hasil (Bahasa Indonesia) 1:

• Antiviral therapy is not recommended and can be deferred in persons without clinical evidence of cirrhosis (or based on APRI score ≤2 in adults), and with persistently normal ALT levels and low levels of HBV DNA replication (HBV DNA <2000 IU/mL), regardless of HBeAg status or age. (Strong recommendation, low quality of evidence) ››Where HBV DNA testing is not available: Treatment can be deferred in HBeAg-positive persons aged 30 years or less and persistently normal ALT levels. (Conditional recommendation, low quality of evidence) • Continued monitoring is necessary in all persons with CHB, but in particular those who do not currently meet the above-recommended criteria for who to treat or not treat, to determine if antiviral therapy may be indicated in the future to prevent progressive liver disease. These include: --persons without cirrhosis aged 30 years or less, with HBV DNA levels >20 000 IU/ mL but persistently normal ALT levels; --HBeAg-negative persons without cirrhosis aged 30 years or less, with HBV DNA levels that fluctuate between 2000 and 20 000 IU/mL, or who have intermittently abnormal ALT levels; ››Where HBV DNA testing is not available: Persons without cirrhosis aged 30 years or less, with persistently normal ALT levels, regardless of HBeAg status